Posted by Michael Wonder on 22 Feb 2017
Pfizer announces acceptance of regulatory submission for inotuzumab ozogamicin by the U.S. FDA
21 February 2017 - Application requests approval for the treatment of relapsed or refractory acute lymphoblastic leukaemia in adults.
Pfizer today announced that a biologics license application for inotuzumab ozogamicin has been accepted for filing and granted priority review by the U.S. FDA.
Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
